Sapu Nano showcases Deciparticle nanomedicine and AI‑driven oncology programs at BIO 2026

Sapu Nano, a biotechnology company focused on oncology, has presented progress on its Deciparticle™ nanomedicine platform at the BIO International Convention 2026 in San Diego, in collaboration with Oncotelic Therapeutics (OTCQX: OTLC). The platform forms ultra-small, sub‑20 nm nanoparticles that enable intravenous delivery of highly water‑insoluble drugs, improving tissue distribution, therapeutic index, and manufacturability while reducing formulation‑related toxicities. Sapu Nano highlighted two lead clinical programs:
Sapu003, an intravenous everolimus formulation already in a Phase 1b trial for mTOR‑sensitive solid tumors, and Sapu006, a Deciparticle‑based docetaxel formulation entering Phase 1. The company also emphasized an AI‑driven oncology development framework that uses Deciparticle‑derived biomarkers to identify tumors most likely to respond to IV nanomedicines, aiming to accelerate precision oncology trials and improve patient selection. Overall, Sapu Nano positioned Deciparticle as a next‑generation platform with broad applicability across hydrophobic drug classes and the potential to expand treatment options in oncology.